Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Number of employees : 267 people.
Sales per Business
20192020Delta
Cancer Care Products272.26100%225.11100% -17.32%
USD in Million
Sales per region
20192020Delta
United States272.26100%225.11100% -17.32%
USD in Million
Managers
Name Title Age Since
Alan H. Auerbach Chairman, President, CEO & Secretary 50 -
Maximo F. Nougues Chief Financial Officer 51 2018
Jay M. Moyes Lead Independent Director 66 -
Troy E. Wilson, Dr. Independent Director 51 2013
Adrian M. Senderowicz, Dr. Independent Director 56 2015
Michael Patrick Miller Independent Director 63 2018
Ann Calby Miller, Dr. Independent Director 62 2019
Brian M. Stuglik Independent Director 61 2020
Mariann Ohanesian Senior Director-Investor Relations - 2012
Jeffrey Ludwig Chief Commercial Officer - -
Members of the board
Name Title Age Since
Alan H. Auerbach Chairman, President, CEO & Secretary 50 -
Jay M. Moyes Lead Independent Director 66 -
Troy E. Wilson, Dr. Independent Director 51 2013
Adrian M. Senderowicz, Dr. Independent Director 56 2015
Michael Patrick Miller Independent Director 63 2018
Ann Calby Miller, Dr. Independent Director 62 2019
Brian M. Stuglik Independent Director 61 2020
Allison Dorval Director 44 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 40,779,030 35,303,627 86.6% 0 0.0% 86.6%
Shareholders
NameEquities%
Alan H. Auerbach 4,417,790 10.8%
Deerfield Management Company LP 3,769,795 9.24%
PFM Health Sciences LP 3,689,538 9.05%
The Vanguard Group, Inc. 3,491,864 8.56%
Fred Alger Management LLC 2,985,976 7.32%
Camber Capital Management LP 2,725,000 6.68%
Ecor1 Capital LLC 2,536,156 6.22%
Consonance Capital Management LP 2,303,455 5.65%
Janus Capital Management LLC 2,170,423 5.32%
Grantham, Mayo, Van Otterloo & Co. LLC 2,010,801 4.93%
Company contact information
Puma Biotechnology, Inc.
10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024

Phone : +1.424.248.6500
Fax : +1.424.248.6501
Web : http://www.pumabiotechnology.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Puma Biotechnology, Inc.
Sector Other Biotechnology & Medical Research